Abstracts tagged "autoantibodies"

Abstract Number: 2138 • 2017 ACR/ARHP Annual Meeting
Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM) are systemic inflammatory diseases that affect skeletal muscle, skin, and other organs, such as lungs,…
Abstract Number: 676 • 2017 ACR/ARHP Annual Meeting
Immunosignature Autoantibody Profiles Provide Mechanistic Insight into Systemic Lupus Erythematosus and Differentiation from Symptomatically Overlapping Diseases
Theodore M. Tarasow¹, Robert Gerwien¹, Jonathan Melnick¹, Scott A. Melville¹ and Chaim Putterman², ¹HealthTell, Inc., San Ramon, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Diagnosis and monitoring of patients with SLE usually requires careful evaluation by a rheumatologist. However, difficulties in accurately quantifing disease and treatment response can…
Abstract Number: 1274 • 2017 ACR/ARHP Annual Meeting
Anti-MDA5 Autoantibodies Associated with Juvenile Dermatomyositis Constitute a Distinct Phenotype in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel⁴, Frederick W Miller² and Lisa G Rider², ¹Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴George Washington University School of Medicine and Health Sciences, Washington, DC
Background/Purpose: Anti-MDA5 autoantibodies (Abs) have been associated with clinically amyopathic and classic dermatomyositis (DM), with rapidly progressive interstitial lung disease (ILD) and poor prognosis in…
Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
Richard Yeker¹, Iago Pinal-Fernandez², Takayuki Kishi³, Ira N. Targoff⁴, Frederick W Miller³, Lisa G Rider³ and Andrew Mammen⁵, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD
Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…
Abstract Number: 691 • 2017 ACR/ARHP Annual Meeting
Serum Anti-NR2 Has a Better Specificity Than Sensitivity in Diagnosing Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)
Seyed-Foad Ahmadi¹, Golara Zahmatkesh², Masoud Majed³ and Sheetal Desai⁴, ¹Department of Medicine, University of California Irvine, Orange, CA, ²Department of Psychiatry, Charles Drew University of Medicine and Science/UCLA, Los Angeles, CA, ³Division of Neuroimmunology, Mayo Clinic, Rochester, MN, ⁴Medicine/Rheumatology, Unviersity of California, Irvine, Orange, CA
Background/Purpose: Anti-NR2, a subclass of anti-NMDA receptor antibodies, is reportedly associated with NPSLE syndromes. However, its diagnostic accuracy is inconsistent across prior studies. Hence, we…
Abstract Number: 1300 • 2017 ACR/ARHP Annual Meeting
The Italian Registry of Autoimmune Congenital Heart Block (Lu.Ne Registry): Report of the First Year of Activity
Micaela Fredi¹, Laura Andreoli², Tiziana Bertero³, Alesandra Bortoluzzi⁴, Silvia Breda⁵, Veronica Cappa⁶, Fulvia Ceccarelli⁷, Rolando Cimaz⁸, Salvatore De Vita⁹, Emma Di Poi¹⁰, Franco Franceschini¹¹, Maria Gerosa¹², Marcello Govoni⁴, Ariela Hoxha¹³, Andrea Lojacono¹⁴, Luca Marozio¹⁵, Alessandro Mathieu¹⁶, Antonina Minniti¹⁷, Marina Muscarà¹⁸, Melissa Padovan⁴, Matteo Piga¹⁶, Roberta Priori⁷, Véronique Ramoni¹⁹, Amelia Ruffatti¹³, Marta Tonello¹³, Sonia Zatti²⁰, Stefano Calza⁶, Antonio Brucato⁵ and Angela Tincani², ¹Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Ospedale Mauriziano, Torino, Italy, ⁴UOC of Rheumatology, University Hospital S. Anna, Cona Ferrara, Italy, ⁵Struttura Complessa Medicina Interna, ASST Papa Giovanni XXIII, Bergamo, Italy, ⁶Unit of Biostatistics and Biomathematics & Unit of Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, ⁷UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Rome, Italy, ⁸Pediatric Rheumatology, Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ⁹Rheumatology Clinic, Academic Hospital S. M. della Misericordia, Medical Area Department, University of Udine, Italy, Udine, Italy, ¹⁰Clinica di Reumatologia, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy, ¹¹Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ¹²Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ¹³Unità di Reumatologia, Dipartimento di Medicina-DIMED, Università di Padova., Padova, Italy, ¹⁴Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, ¹⁵Ginecologia e Ostetricia 1, Dipartimento di Scienze Chirurgiche, Università di Torino, Torino, Italy, ¹⁶Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ¹⁷UO Complessa Reumatologia, Policlinico Umberto I Università Sapienza di Roma, Roma, Italy, ¹⁸Reumatologia ASST Ospedale Niguarda, Milano, Italy, ¹⁹Rheumatology, Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, ²⁰U.O. Ginecologia e Ostetricia ASST Spedali Civili, Brescia, Italy
Background/Purpose: Neonatal Lupus (NL) is a rare syndrome caused by placental transfer of maternal anti-Ro/SSA and anti-La/SSB autoantibodies to the fetus. Cardiac manifestations may comprise…
Abstract Number: 2160 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –
Yuki Ishikawa^1,2, Ran Nakashima¹, Takaki Nojima^3,4, Takuya Isayama⁵, Nobuo Kuramoto¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Clinical Immunology and Rheumatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ³Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Nojima Internal Medicine Clinic, Hiroshima, Japan, ⁵Medical & Biological Laboratories CO.,LTD., Nagoya, Japan
Background/Purpose: Anti-aminoacyl tRNA synthetase (ARS) antibodies are associated with common clinical characters, which are fever, polyarthritis, interstitial lung disease (ILD), Raynaud’s phenomenon, mechanic’s hand and…
Abstract Number: 695 • 2017 ACR/ARHP Annual Meeting
Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies
Petra Budde¹, Hans-Dieter Zucht¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Torsten Witte², Matthias Schneider³ and Peter Schulz-Knappe¹, ¹Protagen AG, Dortmund, Germany, ²Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
Background/Purpose: Given the heterogeneity of clinical presentations, the diagnosis of Systemic Lupus Erythematosus (SLE) can be challenging, in particular in those patients presenting with early…
Abstract Number: 1346 • 2017 ACR/ARHP Annual Meeting
Selective Effect of Rituximab on IgG4 Anti-CCP Autoantibodies in Rheumatoid Arthritis Patients
Mercedes Rincon^1,2, Sarah Kelso³, Janice Bunn⁴ and Sheldon Cooper⁵, ¹Department of Medicine/Rheumatology, University of Vermont, Burlingont VT, VT, ²Department of Medicine/Immunobiology, University of Vermont, Burlington, VT, ³Department of Medicine/Rheumatology, Univeristy of Vermont, Burlington, VT, ⁴Mathematics and Statistics, University of Vermont, Burlington, VT, ⁵Department of Medicine/Rheumatology, University of Vermont, Burlington, VT
Background/Purpose: Autoantibodies have long been recognized to be present in patients with RA, but it is more recent that autoantibodies against citrullinated proteins (anti-CCP) are…
Abstract Number: 2163 • 2017 ACR/ARHP Annual Meeting
Clinical Utilization Patterns and Performance of Commercial Myositis Autoantibody Panels in Routine Practice
Prateek C. Gandiga*¹, Junqian Zhang*², Preethi Thomas¹, Victoria P. Werth^2,3, Sapna Sangani¹, Sharon L. Kolasinski¹ and Michael D. George¹, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ³Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Myositis autoantibody testing is now widely commercially available, with an evolving role in routine clinical care. However, the use and performance of commercial "myositis…
Abstract Number: 707 • 2017 ACR/ARHP Annual Meeting
Distinctive Features of Positive Anti-Cell Antibody Tests on HEp-2 Cells (HEp-2-ANA) in Patients with Non-Autoimmune Diseases
Renan Agustinelli¹, Sílvia H. Rodrigues², Mônica Prado³, Henrique Mariz⁴ and Luis Eduardo C. Andrade^5,6, ¹Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, São Paulo, Brazil, ²Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Internal Medicine Department, Hospital das Clínicas - Universidade Federal de Pernambuco, Recife, Brazil, ⁵Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁶Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: The indirect immunofluorescence (IIF) test for anti-cell or antinuclear (ANA) antibodies on HEp-2 cells (HEp-2-ANA) is considered the gold standard method for ANA detection.…
Abstract Number: 1372 • 2017 ACR/ARHP Annual Meeting
A Single Immunosignature Test Accurately Discriminates RA from Related Autoimmune and Inflammatory Disorders
Theodore M. Tarasow¹, Robert Gerwien¹, Jonathan Melnick¹, Scott A. Melville¹ and Chaim Putterman², ¹HealthTell, Inc., San Ramon, CA, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory autoimmune disease primarily targeting the synovium. RA is B-cell driven, and is associated with autoantibody production. The…
Abstract Number: 2165 • 2017 ACR/ARHP Annual Meeting
Easily Obtainable Myositis Autoantibody Panel Predictive Factors
Jason Weiner¹, Ryan Jessee², Amanda M. Eudy³, Robert T. Keenan⁴, Michael Datto⁵ and Lisa Criscione-Schreiber⁶, ¹Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Duke University Medical Center, Chapel Hill, NC, ⁴Rheumatology, NYU-HJD, New York, NY, ⁵Department of Pathology, Duke University, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Myositis autoantibodies have diagnostic, therapeutic and prognostic implications, but their utility in clinical practice is unclear. We aimed to describe our institutionÕs ordering practices…
Abstract Number: 712 • 2017 ACR/ARHP Annual Meeting
Novel Electronic Health Record Method Reveals That dsDNA Antibody-Negative Systemic Lupus Erythematosus Is Associated with Pain, Sleep, and Mood Disorders
April Barnado¹, Robert Carroll², Carolyn Casey³, Joshua C. Denny² and Leslie Crofford¹, ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, ³Lehigh Valley Health Network, Allentown, PA
Background/Purpose: Systemic lupus is a heterogeneous disease with diverse presentations. Studies have shown that dsDNA antibodies associate with renal disease. However, less is known about…
Abstract Number: 1607 • 2017 ACR/ARHP Annual Meeting
Tumor-Related Autoantibodies and Cancers in SLE: A Case-Control Study from a Single Centre
Sasha Bernatsky¹, Ann E. Clarke², Joyce Rauch³, Christian Pineau⁴, Evelyne Vinet⁵ and Marvin J. Fritzler⁶, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Patients with systemic lupus (SLE) have altered cancer profiles compared to the general population, with a higher risk of some cancers (e.g. lymphoma) and…

« Previous Page
1
…
7
8
9
10
11
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].